Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2018

  • ID: 4576122
  • Drug Pipelines
  • 41 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Ideaya Biosciences Inc
  • Kyn Therapeutics Inc
  • Nippon Kayaku Co Ltd
  • Shenogen Pharma Group Ltd
  • MORE
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2018

Summary:

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 9 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Breast Cancer, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Androgen-Sensitive Prostate Cancer, Celiac Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Inflammatory Bowel Disease, Myasthenia Gravis, Obesity, Ovarian Cancer, Rheumatoid Arthritis and Solid Tumor.

The latest report Aryl Hydrocarbon Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
  • The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ideaya Biosciences Inc
  • Kyn Therapeutics Inc
  • Nippon Kayaku Co Ltd
  • Shenogen Pharma Group Ltd
  • MORE
Introduction

Report Coverage

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Overview

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Companies Involved in Therapeutics Development

Hercules Pharmaceuticals BV

Ideaya Biosciences Inc

Kyn Therapeutics Inc

Nippon Kayaku Co Ltd

Shenogen Pharma Group Ltd

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Drug Profiles

Biologic to Agonize Aryl Hydrocarbon Receptor for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinnabarinic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HP-163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITE - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-150460 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Aryl Hydrocarbon Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Aryl Hydrocarbon Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Dormant Products

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Product Development Milestones

Featured News & Press Releases

Nov 02, 2015: Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer

Sep 15, 2015: Icaritin Enters Fast Track Review for NDA

Sep 18, 2014: Icaritin Ph I Result Presents at 2014 CSCO

Jun 13, 2013: Shenogen Pharma Group: Icaritin Phase II advisory meeting held in Beijing

Jun 07, 2013: Icaritin Phase I data presented at 2013 ASCO Annual Meeting: June 3rd, 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Hercules Pharmaceuticals BV, H1 2018

Pipeline by Ideaya Biosciences Inc, H1 2018

Pipeline by Kyn Therapeutics Inc, H1 2018

Pipeline by Nippon Kayaku Co Ltd, H1 2018

Pipeline by Shenogen Pharma Group Ltd, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Hercules Pharmaceuticals BV
  • Ideaya Biosciences Inc
  • Kyn Therapeutics Inc
  • Nippon Kayaku Co Ltd
  • Shenogen Pharma Group Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll